Findings

What do systematic reviews say?

2,234 questions · 2,325 findings · 216 reviews · Airways

Sort:Best matchNewestHighest certainty Download CSV

No studies found 249 · 10.7%GRADE not reported 107 · 4.6%Very low 276 · 11.9%Low 751 · 32.3%Moderate 718 · 30.9%High 224 · 9.6%

PAAP plus education vs education alone

Serious adverse events (including mortality) · adults with asthma

The review found no eligible studies for this question.

1 finding from 1 review

Personalised asthma action plans for adults with asthma 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

PAAP plus education vs education alone

Change in AQLQ · adults with asthma

1 finding from 1 review

Personalised asthma action plans for adults with asthma 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 174 participants
Low

PAAP plus education vs education alone

Rate of exacerbations requiring systemic corticosteroids · adults with asthma

It is very uncertain whether PAAP plus education changes exacerbation requiring OCS. compared with education alone (very low certainty).

1 finding from 1 review

Personalised asthma action plans for adults with asthma 2017 · Cochrane Headline outcomes only
OR 0.28 [0.07, 1.12]
1 study · 70 participants
Very low

PAAP plus education vs education alone

Lung function · adults with asthma

The review found no eligible studies for this question.

1 finding from 1 review

Personalised asthma action plans for adults with asthma 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

PAAP plus education vs education alone

Days lost from work or study. · adults with asthma

The review found no eligible studies for this question.

1 finding from 1 review

Personalised asthma action plans for adults with asthma 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

PAAP vs no PAAP

Asthma control · adults with asthma

1 finding from 1 review

Personalised asthma action plans for adults with asthma 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 141 participants
Low

PAAP vs no PAAP

Serious adverse events (including mortality) · adults with asthma

It is very uncertain whether PAAP changes serious adverse events (including deaths). compared with no PAAP (very low certainty).

1 finding from 1 review

Personalised asthma action plans for adults with asthma 2017 · Cochrane Headline outcomes only
OR 3.26 [0.33, 32.21]
1 study · 125 participants
Very low

PAAP vs no PAAP

Change in AQLQ · adults with asthma

1 finding from 1 review

Personalised asthma action plans for adults with asthma 2017 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 441 participants
Low

PAAP vs no PAAP

Rate of exacerbations requiring systemic corticosteroids · adults with asthma

It is very uncertain whether PAAP changes exacerbation requiring OCS. compared with no PAAP (very low certainty).

1 finding from 1 review

Personalised asthma action plans for adults with asthma 2017 · Cochrane Headline outcomes only
OR 1.45 [0.84, 2.48]
3 studies · 1136 participants
Very low

PAAP vs no PAAP

Lung function: FEV1 mL (change from baseline) · adults with asthma

1 finding from 1 review

Personalised asthma action plans for adults with asthma 2017 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 392 participants
Low

PAAP vs no PAAP

Days lost from work or study. · adults with asthma

1 finding from 1 review

Personalised asthma action plans for adults with asthma 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 74 participants
Low

PAAP plus education vs education alone

Rate of exacerbations requiring emergency department treatment or admission · adults with asthma

It is very uncertain whether PAAP plus education changes exacerbation requiring ED or hospitalisation. compared with education alone (very low certainty).

1 finding from 1 review

Personalised asthma action plans for adults with asthma 2017 · Cochrane Headline outcomes only
OR 1.08 [0.27, 4.32]
1 study · 70 participants
Very low

PAAP plus education vs education alone

Asthma control · adults with asthma

1 finding from 1 review

Personalised asthma action plans for adults with asthma 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 70 participants
Low

Umeclidinium bromide vs placebo

Exacerbations requiring steroids or antibiotics or both: number of participants · patients with chronic obstructive pulmonary disease

Umeclidinium bromide leads to lower number of participants with exacerbations requiring steroids,… compared with placebo (high certainty).

1 finding from 1 review

Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD) 2017 · Cochrane Headline outcomes only
OR 0.61 [0.46, 0.8]
4 studies · 1922 participants
High

Umeclidinium bromide vs placebo

Quality of life: number of participants with clinically significant improvement (≥ 4 units) in SGRQ total score · patients with chronic obstructive pulmonary disease

Umeclidinium bromide probably leads to higher quality of life: number of participants with ≥ 4 units improvement… compared with placebo (moderate certainty).

1 finding from 1 review

Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD) 2017 · Cochrane Headline outcomes only
OR 1.45 [1.16, 1.82]
3 studies · 1397 participants
Moderate

Umeclidinium bromide vs placebo

Non‐fatal serious adverse events · patients with chronic obstructive pulmonary disease

Umeclidinium bromide showed no clear difference in non‐fatal serious adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD) 2017 · Cochrane Headline outcomes only
OR 1.33 [0.89, 2]
4 studies · 1922 participants
Moderate

Umeclidinium bromide vs placebo

Hospitalisations due to COPD exacerbations · patients with chronic obstructive pulmonary disease

Umeclidinium bromide showed no clear difference in number of participants with hospital admissions due to COPD… compared with placebo (low certainty).

1 finding from 1 review

Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD) 2017 · Cochrane Headline outcomes only
OR 0.86 [0.25, 2.92]
4 studies · 1922 participants
Low

Umeclidinium bromide vs placebo

Improvement in symptoms: number of participants with clinically significant improvement: using TDI focal score (≥ 1 unit) · patients with chronic obstructive pulmonary disease

Umeclidinium bromide leads to higher number of participants with ≥ 1 unit improvement in TDI focal score compared with placebo (high certainty).

1 finding from 1 review

Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD) 2017 · Cochrane Headline outcomes only
OR 1.71 [1.37, 2.15]
3 studies · 1441 participants
High

Umeclidinium bromide vs placebo

Change in baseline trough FEV1 · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD) 2017 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 1381 participants
High

Umeclidinium bromide vs placebo

Adverse events (not including serious adverse events): number of participants · patients with chronic obstructive pulmonary disease

Umeclidinium bromide showed no clear difference in adverse events (not including serious adverse events) compared with placebo (moderate certainty).

1 finding from 1 review

Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD) 2017 · Cochrane Headline outcomes only
OR 1.06 [0.85, 1.31]
4 studies · 1922 participants
Moderate